BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 27980219)

  • 1. Overactive mTOR signaling leads to endometrial hyperplasia in aged women and mice.
    Bajwa P; Nielsen S; Lombard JM; Rassam L; Nahar P; Rueda BR; Wilkinson JE; Miller RA; Tanwar PS
    Oncotarget; 2017 Jan; 8(5):7265-7275. PubMed ID: 27980219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Age related increase in mTOR activity contributes to the pathological changes in ovarian surface epithelium.
    Bajwa P; Nagendra PB; Nielsen S; Sahoo SS; Bielanowicz A; Lombard JM; Wilkinson JE; Miller RA; Tanwar PS
    Oncotarget; 2016 Apr; 7(15):19214-27. PubMed ID: 27036037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 Is highly responsive to mTOR inhibition.
    Cheng H; Liu P; Zhang F; Xu E; Symonds L; Ohlson CE; Bronson RT; Maira SM; Di Tomaso E; Li J; Myers AP; Cantley LC; Mills GB; Zhao JJ
    Cancer Res; 2014 Jan; 74(1):15-23. PubMed ID: 24322983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adipose-Derived VEGF-mTOR Signaling Promotes Endometrial Hyperplasia and Cancer: Implications for Obese Women.
    Sahoo SS; Lombard JM; Ius Y; O'Sullivan R; Wood LG; Nahar P; Jaaback K; Tanwar PS
    Mol Cancer Res; 2018 Feb; 16(2):309-321. PubMed ID: 29133593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors.
    Philip CA; Laskov I; Beauchamp MC; Marques M; Amin O; Bitharas J; Kessous R; Kogan L; Baloch T; Gotlieb WH; Yasmeen A
    BMC Cancer; 2017 Sep; 17(1):638. PubMed ID: 28886696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced progression of endometrial hyperplasia with oral mTOR inhibition in the Pten heterozygote murine model.
    Milam MR; Celestino J; Wu W; Broaddus RR; Schmeler KM; Slomovitz BM; Soliman PT; Gershenson DM; Wang H; Ellenson LH; Lu KH
    Am J Obstet Gynecol; 2007 Mar; 196(3):247.e1-5. PubMed ID: 17346540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conditional abrogation of transforming growth factor-β receptor 1 in PTEN-inactivated endometrium promotes endometrial cancer progression in mice.
    Gao Y; Lin P; Lydon JP; Li Q
    J Pathol; 2017 Sep; 243(1):89-99. PubMed ID: 28657664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of mTOR inhibitors in nude mice with endometrial carcinoma and variable PTEN expression status.
    Fong P; Meng LR
    Med Sci Monit Basic Res; 2014 Sep; 20():146-52. PubMed ID: 25266877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term estradiol exposure is a direct mitogen for insulin/EGF-primed endometrial cells and drives PTEN loss-induced hyperplasic growth.
    Eritja N; Mirantes C; Llobet D; Yeramian A; Bergadà L; Dosil MA; Domingo M; Matias-Guiu X; Dolcet X
    Am J Pathol; 2013 Jul; 183(1):277-87. PubMed ID: 23669345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An inducible knockout mouse to model the cell-autonomous role of PTEN in initiating endometrial, prostate and thyroid neoplasias.
    Mirantes C; Eritja N; Dosil MA; Santacana M; Pallares J; Gatius S; Bergadà L; Maiques O; Matias-Guiu X; Dolcet X
    Dis Model Mech; 2013 May; 6(3):710-20. PubMed ID: 23471917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stromal liver kinase B1 [STK11] signaling loss induces oviductal adenomas and endometrial cancer by activating mammalian Target of Rapamycin Complex 1.
    Tanwar PS; Kaneko-Tarui T; Zhang L; Tanaka Y; Crum CP; Teixeira JM
    PLoS Genet; 2012; 8(8):e1002906. PubMed ID: 22916036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models.
    Gozgit JM; Squillace RM; Wongchenko MJ; Miller D; Wardwell S; Mohemmad Q; Narasimhan NI; Wang F; Clackson T; Rivera VM
    Cancer Chemother Pharmacol; 2013 May; 71(5):1315-23. PubMed ID: 23468082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer.
    Mackay HJ; Eisenhauer EA; Kamel-Reid S; Tsao M; Clarke B; Karakasis K; Werner HM; Trovik J; Akslen LA; Salvesen HB; Tu D; Oza AM
    Cancer; 2014 Feb; 120(4):603-10. PubMed ID: 24166148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lkb1 inactivation is sufficient to drive endometrial cancers that are aggressive yet highly responsive to mTOR inhibitor monotherapy.
    Contreras CM; Akbay EA; Gallardo TD; Haynie JM; Sharma S; Tagao O; Bardeesy N; Takahashi M; Settleman J; Wong KK; Castrillon DH
    Dis Model Mech; 2010; 3(3-4):181-93. PubMed ID: 20142330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New strategies in endometrial cancer: targeting the PI3K/mTOR pathway--the devil is in the details.
    Myers AP
    Clin Cancer Res; 2013 Oct; 19(19):5264-74. PubMed ID: 24089439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer-associated fibroblasts promote proliferation of endometrial cancer cells.
    Subramaniam KS; Tham ST; Mohamed Z; Woo YL; Mat Adenan NA; Chung I
    PLoS One; 2013; 8(7):e68923. PubMed ID: 23922669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The uterine epithelial loss of Pten is inefficient to induce endometrial cancer with intact stromal Pten.
    Liang X; Daikoku T; Terakawa J; Ogawa Y; Joshi AR; Ellenson LH; Sun X; Dey SK
    PLoS Genet; 2018 Aug; 14(8):e1007630. PubMed ID: 30142194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. mTOR transcriptionally and post-transcriptionally regulates Npm1 gene expression to contribute to enhanced proliferation in cells with Pten inactivation.
    Boudra R; Lagrafeuille R; Lours-Calet C; de Joussineau C; Loubeau-Legros G; Chaveroux C; Saru JP; Baron S; Morel L; Beaudoin C
    Cell Cycle; 2016 May; 15(10):1352-62. PubMed ID: 27050906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapamycin inhibits telomerase activity by decreasing the hTERT mRNA level in endometrial cancer cells.
    Zhou C; Gehrig PA; Whang YE; Boggess JF
    Mol Cancer Ther; 2003 Aug; 2(8):789-95. PubMed ID: 12939469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oestrogen fuels the growth of endometrial hyperplastic lesions initiated by overactive Wnt/β-catenin signalling.
    Goad J; Ko YA; Kumar M; Jamaluddin MFB; Tanwar PS
    Carcinogenesis; 2018 Sep; 39(9):1105-1116. PubMed ID: 29912292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.